TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29858465

Group type: EXPERIMENTAL
Intervention: Cadence ≥100 steps/min
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Peak 1-min cadence
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Peak 30-min cadence
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low mean daily cadences
Number of subjects: 38
Study: 29858547

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 29859038

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (8-week group intervention)
Number of subjects: 110
Study: 29859084

Group type: EXPERIMENTAL
Intervention: Use of toothbrush and toothpaste at least once a day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oral rinse during pregnancy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Knowledge of dental care
Number of subjects: 39
Study: 29859740

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir-voxilaprevir (400 mg sofosbuvir, 100 mg velpatasvir, 100 mg voxilaprevir once daily for 12 weeks)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir-voxilaprevir
Number of subjects: 147
Study: 29859785

Group type: EXPERIMENTAL
Intervention: Elekta Clarity Autoscan system for ultrasound-based intrafraction motion estimation
Number of subjects: 16
Study: 29859851

Group type: EXPERIMENTAL
Intervention: Quizartinib 135 mg/day for men and 90 mg/day for women (oral solution)
Number of subjects: 333
Study: 29859908

Group type: EXPERIMENTAL
Intervention: Metabolically healthy obesity
Number of subjects: 90257

Group type: EXPERIMENTAL
Intervention: Metabolically unhealthy normal weight
Number of subjects: 90257

Group type: EXPERIMENTAL
Intervention: Metabolically unhealthy overweight
Number of subjects: 90257

Group type: EXPERIMENTAL
Intervention: Metabolically unhealthy obesity
Number of subjects: 90257

Group type: EXPERIMENTAL
Intervention: Maintained metabolically healthy obesity
Number of subjects: 90257

Group type: EXPERIMENTAL
Intervention: Converted to unhealthy phenotype (normal-weight)
Number of subjects: 90257

Group type: EXPERIMENTAL
Intervention: Converted to unhealthy phenotype (obesity)
Number of subjects: 90257
Study: 29859909

Group type: EXPERIMENTAL
Intervention: Sufficient preconception 25-hydroxyvitamin D (≥75 nmol/L)
Number of subjects: 1191

Group type: COMPARATOR
Intervention: Insufficient preconception 25-hydroxyvitamin D (<75 nmol/L)
Number of subjects: 1191
Study: 29859993

Group type: EXPERIMENTAL
Intervention: HbA1c <70mmol/mol (<8.6%)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: HbA1c [40-50) mmol/mol ([5.8-6.7) %)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: HbA1c [50-70) mmol/mol ([6.7-8.6) %) or <40mmol/mol (<5.8%)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: HbA1c ≥70mmol/mol (≥8.6%)
Number of subjects: 987
Study: 29860039

Group type: EXPERIMENTAL
Intervention: TLR4 polymorphisms (TLR4-Asp299Gly, TLR4-Thr399Ile)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: TLR9-T1237C polymorphism
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: TLR4 polymorphisms
Number of subjects: 224
Study: 29860938

Group type: EXPERIMENTAL
Intervention: Ivosidenib 500 mg daily
Number of subjects: 258
Study: 29861102

Group type: EXPERIMENTAL
Intervention: Interventional left atrial appendage closure (LAAC)
Number of subjects: 44
Study: 29861390

Group type: EXPERIMENTAL
Intervention: High basal and low stimulated lipolysis at baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low stimulated lipolysis
Number of subjects: 0
Study: 29861609

Group type: EXPERIMENTAL
Intervention: Endoscopic Screening for Esophageal Cancer (ESECC) trial
Number of subjects: 12085
Study: 29861796

Group type: EXPERIMENTAL
Intervention: Plasma levels of total soluble RAGE (sRAGE) and endogenous secretory (es)RAGE measured by duplicate ELISA
Number of subjects: 294
Study: 29862011

Group type: EXPERIMENTAL
Intervention: Mild to moderate COPD subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Asymptomatic current smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy former smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy never-smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mild to moderate COPD
Number of subjects: 0
Study: 29862030

Group type: EXPERIMENTAL
Intervention: EDIT management (elastance-directed intrapleural catheter)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (attempt at talc pleurodesis)
Number of subjects: 0
Study: 29862031

Group type: EXPERIMENTAL
Intervention: HD+ bronchoscopy with i-scan image enhancement
Number of subjects: 107
Study: 29862225

Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogue cessation
Number of subjects: 92
Study: 29862269

Group type: EXPERIMENTAL
Intervention: Short implants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional implants
Number of subjects: 0
Study: 29862286

Group type: EXPERIMENTAL
Intervention: Low torque group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High torque group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Medium torque group
Number of subjects: 75
Study: 29862437

Group type: EXPERIMENTAL
Intervention: Fludarabine and rituximab with escalating doses of lenalidomide
Number of subjects: 45
Study: 29862466

Group type: EXPERIMENTAL
Intervention: Piperacillin (extended and continuous infusion)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard intermittent piperacillin dosing regimens
Number of subjects: 50
Study: 29862506

Group type: EXPERIMENTAL
Intervention: OAMS framework integrated coaching
Number of subjects: 666
Study: 29862656

Group type: EXPERIMENTAL
Intervention: Heavy silicone oil (Densiron-68™ HSO)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard silicone oil (PDMS)
Number of subjects: 35
Study: 29863313

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29863388

Group type: EXPERIMENTAL
Intervention: 50 mg amitriptyline on four consecutive days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 40
Study: 29863899

Group type: EXPERIMENTAL
Intervention: Optimal step-down therapy with moderate-dose combination inhaled corticosteroids/long-acting β-agonists
Number of subjects: 0
Study: 29863979

Group type: EXPERIMENTAL
Intervention: Cemiplimab (3 mg/kg every 2 weeks)
Number of subjects: 85
Study: 29864044

Group type: EXPERIMENTAL
Intervention: Topical dorzolamide-timolol, administered as one drop twice daily for the duration of the study.
Number of subjects: 8
Study: 29864089

Group type: EXPERIMENTAL
Intervention: Minimally invasive pancreatoduodenectomy (MIPD)
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Laparoscopic MIPD
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Robot-assisted MIPD
Number of subjects: 729
Study: 29865778

Group type: EXPERIMENTAL
Intervention: Negative pp65-specific ELISPOT results (< 11 spots/200,000 cells)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Positive pp65-specific ELISPOT results (≥ 11 spots/200,000 cells)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Negative pp65-specific ELISPOT assay results
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 133
Study: 29866196

Group type: EXPERIMENTAL
Intervention: Modified Paleolithic diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low saturated fat diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 0
Study: 29866200

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program for 4 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Baseline SPPB-scores
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Changes in SPPB-scores
Number of subjects: 45
Study: 29866202

Group type: EXPERIMENTAL
Intervention: Managed transition interventions
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Current service provision and new transition-related measures
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Longitudinal outcomes for young people leaving CAMHS
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Training modules for clinicians
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Commissioning and policy guidelines for service providers
Number of subjects: 1000
Study: 29866619

Group type: EXPERIMENTAL
Intervention: Total vessel analysis combined with stenosis for ischemia
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Proximal LD-NCP evaluation
Number of subjects: 254

Group type: COMPARATOR
Intervention: Stenosis alone
Number of subjects: 254
Study: 29866628

Group type: EXPERIMENTAL
Intervention: 75-g Oral Glucose Tolerance Test (OGTT) in PD patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy controls (CT)
Number of subjects: 50
Study: 29866789

Group type: EXPERIMENTAL
Intervention: Multispecies probiotic (Winclove 612)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 350
Study: 29866794

Group type: EXPERIMENTAL
Intervention: Presence of any pathogen
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: Nonrhinovirus pathogens
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: Respiratory syncytial virus
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: Influenza
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: Parainfluenza
Number of subjects: 958
Study: 29867173

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 5025
Study: 29867602

Group type: EXPERIMENTAL
Intervention: ketamine + ECT
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: sequence of treatments
Number of subjects: 15

Group type: COMPARATOR
Intervention: ketamine + sham ECT
Number of subjects: 15
Study: 29867616

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29867646

Group type: EXPERIMENTAL
Intervention: Stress Reduction Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study: 29867717

Group type: EXPERIMENTAL
Intervention: Target-to-target pointing task in VR for individuals with stroke (mild and moderate)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Target-to-target pointing task in VR for healthy controls
Number of subjects: 67
Study: 29867728

Group type: EXPERIMENTAL
Intervention: Active CPAP (6 months)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham CPAP (3 months) followed by active CPAP (6 months)
Number of subjects: 62
Study: 29867923

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (aHSCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural Killer (NK) cell reconstitution
Number of subjects: 0
Study: 29867922

Group type: EXPERIMENTAL
Intervention: SV-BR-1-GM, a GM-CSF-secreting breast tumor cell line
Number of subjects: 1
Study: 29867930

Group type: EXPERIMENTAL
Intervention: Multidrug therapy (MDT)
Number of subjects: 0
Study: 29868357

Group type: EXPERIMENTAL
Intervention: Summertime weight-gain prevention intervention
Number of subjects: 51

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 51
Study: 29868473

Group type: EXPERIMENTAL
Intervention: Triapine-cisplatin-radiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin-radiation
Number of subjects: 0
Study: 29868792

Group type: EXPERIMENTAL
Intervention: Pre-vaccination expectation of side effects
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Media suggestions, NHS vaccination leaflet, health care workers' suggestions, uncertainty-related beliefs, perceived sensitivity to medicines, pessimism, and anxiety
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Side effect perception
Number of subjects: 270
Study: 29868913

Group type: EXPERIMENTAL
Intervention: Even-chain saturated fatty acids (SFAs) concentrations
Number of subjects: 2802

Group type: EXPERIMENTAL
Intervention: Odd-chain saturated fatty acids (SFAs) concentrations
Number of subjects: 2802

Group type: EXPERIMENTAL
Intervention: Palmitic acid (16:0)
Number of subjects: 2802

Group type: EXPERIMENTAL
Intervention: Pentadecanoic acid (15:0)
Number of subjects: 2802

Group type: EXPERIMENTAL
Intervention: Heptadecanoic acid (17:0)
Number of subjects: 2802

Group type: EXPERIMENTAL
Intervention: High even-chain SFA concentrations and low odd-chain SFAs
Number of subjects: 2802

Group type: EXPERIMENTAL
Intervention: Even-chain and odd-chain SFAs
Number of subjects: 2802
Study: 29869084

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1591

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1591
Study: 29869107

Group type: EXPERIMENTAL
Intervention: Luteal phase ovarian stimulation (LPOS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Follicular phase ovarian stimulation (FPOS)
Number of subjects: 60
Study: 29869523

Group type: EXPERIMENTAL
Intervention: G1 (T2D with acute CF)
Number of subjects: 51

Group type: COMPARATOR
Intervention: G2 (T2D with equivalent neuropathy)
Number of subjects: 51
Study: 29869534

Group type: EXPERIMENTAL
Intervention: Subretinal injection of rAAV2-CB-hRPE65
Number of subjects: 12
Study: 29869835

Group type: EXPERIMENTAL
Intervention: OPT-CAD score (risk scoring system based on 10 independent risk factors)
Number of subjects: 14032

Group type: EXPERIMENTAL
Intervention: OPT-CAD score
Number of subjects: 14032
Study: 29869957

Group type: EXPERIMENTAL
Intervention: Emphysema with interstitial features
Number of subjects: 8266
Study: 29870382

Group type: EXPERIMENTAL
Intervention: ΔHgb <1.0 g/dL
Number of subjects: 7608

Group type: EXPERIMENTAL
Intervention: ΔHgb ≥1.0 to <2.0 g/dL
Number of subjects: 7608

Group type: EXPERIMENTAL
Intervention: ΔHgb ≥2.0 to <3.0 g/dL
Number of subjects: 7608

Group type: EXPERIMENTAL
Intervention: ΔHgb ≥3.0 to <4.0 g/dL
Number of subjects: 7608

Group type: EXPERIMENTAL
Intervention: ΔHgb ≥4.0 g/dL
Number of subjects: 7608
Study: 29870396

Group type: EXPERIMENTAL
Intervention: Chronic Pain Grade
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Mainz Pain Stage
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Patients
Number of subjects: 355

Group type: COMPARATOR
Intervention: Employees
Number of subjects: 355
Study: 29871514

Group type: EXPERIMENTAL
Intervention: NeuroRegen scaffolds with human umbilical cord mesenchymal stem cells (MSCs)
Number of subjects: 2
Study: 29871595

Group type: EXPERIMENTAL
Intervention: mHealth recommender system delivering tailored motivational health messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mHealth recommender system
Number of subjects: 0
Study: 29871795

Group type: EXPERIMENTAL
Intervention: Transvaginal oocyte retrieval procedures
Number of subjects: 12615
Study: 29871852

Group type: COMPARATOR
Intervention: Usual case management
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Usual case management plus smartphone
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Usual case management with a study-provided smartphone that is preloaded with an innovative case management app
Number of subjects: 432
Study: 29871853

Group type: EXPERIMENTAL
Intervention: Web-based positive emotion skills intervention (MARIGOLD)
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Enhancement strategies (facilitator contact, online discussion board, virtual badges)
Number of subjects: 735
Study: 29871940

Group type: EXPERIMENTAL
Intervention: Pulsta valve implantation
Number of subjects: 10
Study: 29862011

Group type: EXPERIMENTAL
Intervention: Mild-to-moderate COPD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Currently smoking asymptomatic subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy former smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy subjects that had never smoked
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mild-to-moderate COPD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Currently smoking asymptomatic subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy former smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy subjects that had never smoked
Number of subjects: 0
Study: 29872570

Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) lymphodepletion prior to CAR T-cell therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: CAR T-cell therapy alone
Number of subjects: 0
Study: 29873008

Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 107
Study: 29873679

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 508

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 508
Study: 29873682

Group type: EXPERIMENTAL
Intervention: Loss of control over eating (LOC) during pregnancy
Number of subjects: 11132

Group type: EXPERIMENTAL
Intervention: Frequent LOC during pregnancy
Number of subjects: 11132

Group type: EXPERIMENTAL
Intervention: Occasional LOC during pregnancy
Number of subjects: 11132

Group type: EXPERIMENTAL
Intervention: Offspring of mothers with frequent LOC
Number of subjects: 11132
Study: 29873894

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 2037
Study: 29874098

Group type: EXPERIMENTAL
Intervention: PRISm at phase 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRISm at both phase 1 and phase 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRISm
Number of subjects: 0
Study: 29874177

Group type: EXPERIMENTAL
Intervention: Next-generation sequencing of a custom panel of 35 genes (12 for inherited long- and short-QT syndrome genes and 23 additional candidate genes)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Functional significance examination by patch-clamp electrophysiological recording
Number of subjects: 242
Study: 29874546

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 11
Study: 29875066

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for about 2 years or until disease progression, unacceptable toxicity, patient withdrawal, or investigator decision.
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Pembrolizumab treatment
Number of subjects: 104
Study: 29875084

Group type: EXPERIMENTAL
Intervention: Tablet-based decision support tool
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard verbal presentation of material
Number of subjects: 0
Study: 29875139

Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 1605
Study: 29876282

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 28
Study: 29876358

Group type: EXPERIMENTAL
Intervention: Radiofrequency Renal Denervation (RDN)
Number of subjects: 13
Study: 29876839

Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: One-anastomosis Gastric Bypass (OAGB)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Control (Preoperative)
Number of subjects: 468
Study: 29876999

Group type: EXPERIMENTAL
Intervention: Geophagy during pregnancy
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Geophagy during the third trimester and throughout pregnancy
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Prenatal geophagy with micronutrient supplementation
Number of subjects: 552
Study: 29877131

Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A (BOTOX®)
Number of subjects: 10
Study: 29877739

Group type: EXPERIMENTAL
Intervention: Long-term macrolide therapy for refractory MAC-LD, median duration of treatment 32 months (interquartile range, 24-41 mo)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Molecular analysis of isolates from patients
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mycobacterial genotyping of stored pre- and post-treatment isolates
Number of subjects: 72
Study: 29877768

Group type: EXPERIMENTAL
Intervention: Bilateral FFA and OFA activity during featural/configural difference judgments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bilateral FFA and OFA activity during distinct exemplar differentiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnitude of activity within FFA and OFA during chair task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnitude of activity within FFA and OFA during distinct chair exemplar differentiation
Number of subjects: 0
Study: 29877990

Group type: EXPERIMENTAL
Intervention: Group Visits (GVs)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Individual Visits (INDs)
Number of subjects: 91
Study: 29878058

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) intervention (800 kcal/d) for 8 weeks
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Simplified model based on baseline Matsuda index, proline, and phosphatidylcholine 0-34:1
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Homeostasis model assessment of insulin resistance
Number of subjects: 433
Study: 29878087

Group type: EXPERIMENTAL
Intervention: Patients failing to recognize symptoms as cardiac
Number of subjects: 3434

Group type: EXPERIMENTAL
Intervention: Patients with rural medical insurance
Number of subjects: 3434

Group type: EXPERIMENTAL
Intervention: Patients with household income of 10,000-50,000 RMB
Number of subjects: 3434

Group type: EXPERIMENTAL
Intervention: Patients with household income of <10,000 RMB
Number of subjects: 3434
Study: 29878100

Group type: EXPERIMENTAL
Intervention: JIA patients with TMJ arthritis
Number of subjects: 62
Study: 29878653

Group type: EXPERIMENTAL
Intervention: Adeno-associated viral vectors (AAV) gene therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incorporation of a hyperactive gain-of-function R338L mutation (FIX Padua)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High vector doses of AAV gene therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene-editing approaches (ZFN and CRISPR/Cas)
Number of subjects: 0
Study: 29878866

Group type: EXPERIMENTAL
Intervention: Treatment for progressive midgut neuroendocrine tumors (specific intervention details not provided)
Number of subjects: 0
Study: 29878989

Group type: EXPERIMENTAL
Intervention: Inframammary fold incision
Number of subjects: 79

Group type: COMPARATOR
Intervention: Lateral radial incision
Number of subjects: 79
Study: 29879010

Group type: EXPERIMENTAL
Intervention: Microbotox technique (154 U)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Microbotox technique
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nefertiti technique
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 25